Angiogenesis inhibitors and radiation in multimodality cancer therapy: Preclinical and clinical studies

Jennifer Vogel, Kevin Camphausen

Research output: Contribution to journalReview article

Abstract

Radiation, chemotherapy, and surgery share roles in modern cancer therapy targeting neoplastic tumor cells. Greater understanding of the importance of angiogenesis and tumor neovascularization in oncology has led to development of another therapeutic modality, angiogenesis inhibitors, which specifically target the tumor vasculature. Antiangiogenic agents have been shown to act synergistically with traditional cytotoxic treatments, including radiation, against a variety of tumor histologies. Their selective incorporation in multimodality therapy based on tumor type, angiogenic profile, and individual patient response offers the potential for greater disease control. In this review we summarize studies evaluating angiogenesis inhibitors combined with radiation in cancer therapy, and progress made towards optimally incorporating these agents into established treatment regimens.

Original languageEnglish (US)
Pages (from-to)157-167
Number of pages11
JournalCurrent Angiogenesis
Volume1
Issue number2
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Angiogenesis Inhibitors
Radiation
Neoplasms
Therapeutics
Clinical Studies
Histology
Drug Therapy

Keywords

  • Angiogenesis
  • Angiogenesis inhibitors
  • Antiangiogenic therapy
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Angiogenesis inhibitors and radiation in multimodality cancer therapy : Preclinical and clinical studies. / Vogel, Jennifer; Camphausen, Kevin.

In: Current Angiogenesis, Vol. 1, No. 2, 01.01.2012, p. 157-167.

Research output: Contribution to journalReview article

@article{b74cb3ee3a6f493fa784a16ef44b002e,
title = "Angiogenesis inhibitors and radiation in multimodality cancer therapy: Preclinical and clinical studies",
abstract = "Radiation, chemotherapy, and surgery share roles in modern cancer therapy targeting neoplastic tumor cells. Greater understanding of the importance of angiogenesis and tumor neovascularization in oncology has led to development of another therapeutic modality, angiogenesis inhibitors, which specifically target the tumor vasculature. Antiangiogenic agents have been shown to act synergistically with traditional cytotoxic treatments, including radiation, against a variety of tumor histologies. Their selective incorporation in multimodality therapy based on tumor type, angiogenic profile, and individual patient response offers the potential for greater disease control. In this review we summarize studies evaluating angiogenesis inhibitors combined with radiation in cancer therapy, and progress made towards optimally incorporating these agents into established treatment regimens.",
keywords = "Angiogenesis, Angiogenesis inhibitors, Antiangiogenic therapy, Radiotherapy",
author = "Jennifer Vogel and Kevin Camphausen",
year = "2012",
month = "1",
day = "1",
doi = "10.2174/2211552811201020157",
language = "English (US)",
volume = "1",
pages = "157--167",
journal = "Current Angiogenesis",
issn = "2211-5528",
publisher = "Bentham Science Publishers",
number = "2",

}

TY - JOUR

T1 - Angiogenesis inhibitors and radiation in multimodality cancer therapy

T2 - Preclinical and clinical studies

AU - Vogel, Jennifer

AU - Camphausen, Kevin

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Radiation, chemotherapy, and surgery share roles in modern cancer therapy targeting neoplastic tumor cells. Greater understanding of the importance of angiogenesis and tumor neovascularization in oncology has led to development of another therapeutic modality, angiogenesis inhibitors, which specifically target the tumor vasculature. Antiangiogenic agents have been shown to act synergistically with traditional cytotoxic treatments, including radiation, against a variety of tumor histologies. Their selective incorporation in multimodality therapy based on tumor type, angiogenic profile, and individual patient response offers the potential for greater disease control. In this review we summarize studies evaluating angiogenesis inhibitors combined with radiation in cancer therapy, and progress made towards optimally incorporating these agents into established treatment regimens.

AB - Radiation, chemotherapy, and surgery share roles in modern cancer therapy targeting neoplastic tumor cells. Greater understanding of the importance of angiogenesis and tumor neovascularization in oncology has led to development of another therapeutic modality, angiogenesis inhibitors, which specifically target the tumor vasculature. Antiangiogenic agents have been shown to act synergistically with traditional cytotoxic treatments, including radiation, against a variety of tumor histologies. Their selective incorporation in multimodality therapy based on tumor type, angiogenic profile, and individual patient response offers the potential for greater disease control. In this review we summarize studies evaluating angiogenesis inhibitors combined with radiation in cancer therapy, and progress made towards optimally incorporating these agents into established treatment regimens.

KW - Angiogenesis

KW - Angiogenesis inhibitors

KW - Antiangiogenic therapy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84864253660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864253660&partnerID=8YFLogxK

U2 - 10.2174/2211552811201020157

DO - 10.2174/2211552811201020157

M3 - Review article

AN - SCOPUS:84864253660

VL - 1

SP - 157

EP - 167

JO - Current Angiogenesis

JF - Current Angiogenesis

SN - 2211-5528

IS - 2

ER -